Hypericin Protects Islet Β-Cells Against Glucotoxicity and Lipotoxicity in Vitro and in Vivo and Prevents the Onset of Diabetes

Chen Liang,Fang Hao,Xinlei Yao,Ye Qiu,Lei Liu,Shuyue Wang,Chunlei Yu,Zhenbo Song,Yongli Bao,Jingwen Yi,Yanxin Huang,Yin Wu,Lihua Zheng,Ying Sun,Guannan Wang,Xiaoguang Yang,Shaonian Yang,Luguo Sun,Yuxin Li
DOI: https://doi.org/10.2139/ssrn.3237705
2018-01-01
Abstract:A decrease in islet β-cell mass is closely associated with the development and progression of diabetes. Therefore, protection against β-cell loss is one of the essential ways to prevent or treat diabetes. In this study, we investigated the protective effects of non-photoactivated hypericin, a natural compound, on β-cells both in vitro and in vivo. In vitro, hypericin greatly improved INS-1 cell viability under high glucose and high fatty acid conditions through the inhibition of glucotoxicity- and lipotoxicity-induced apoptosis and nitric oxygen (NO) production. Then, we further demonstrated that hypericin elicited its protective effects on INS-1 cells against glucotoxicity and lipotoxicity by activating Erk signalling and promoting pancreatic duodenal homeobox-1 (PDX1) expression. In vivo, prophylactic use of hypericin inhibited islet β-cell apoptosis and enhanced the anti-oxidative ability of pancreatic tissue in high-fat diet (HFD)-fed mice, thus alleviating β-cell loss and maintaining β-cell mass and islet size. More importantly, prophylactic treatment with hypericin decreased fasting blood glucose, improved glucose intolerance and insulin intolerance, and alleviated hyperinsulinaemia of HFD-fed mice. Therefore, hypericin showed preventive effects against the onset of type II diabetes in mice. Hypericin possesses great potential to be developed as a preventive or therapeutic anti-diabetes drug in the future.
What problem does this paper attempt to address?